Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant envafolimab plus platinum-based chemotherapy for resectable stage II-IIIB non-small cell lung cancer
ChiCTR2300069820Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Oct 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Major Pathologic Response. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300069820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069820.